INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Efficacy for Sustained Use of Topical Dorzolamide for Treatment of Cystic Macular Lesions in Patients with X-Linked Retinoschisis (XLRS)

Show full item record

Bookmark or cite this item:

Files in this item

File Description Format
PDF Trusopt in XLRS Final-3.pdf (243KB) Main article PDF
JPEG image Figure 1.jpg (2MB) Figure 1 JPEG image
Title: Efficacy for Sustained Use of Topical Dorzolamide for Treatment of Cystic Macular Lesions in Patients with X-Linked Retinoschisis (XLRS)
Author(s): Genead, Mohamed A.; Fishman, Gerald A.; Walia, Saloni
Abstract: Objectives: To determine the efficacy for sustained use of topical 2% dorzolamide on visual acuity (VA) and macular cystic-appearing lesions in XLRS patients. Design: Retrospective analysis. Setting: University hospital tertiary care referral. Patients: Twenty nine eyes of 15 patients with XLRS on treatment with topical 2% dorzolamide for a duration ranged from 4-41 months were enrolled. Main Outcome Measures: Changes in VA, cystic macular lesions, and central foveal zone (CFZ) thickness on optical coherence tomography over a treatment duration follow-up (FU) period. Results: Among the 15 patients with XLRS, 20 eyes (68.9%) of 11 patients showed a positive response to treatment. Five of the 20 eyes (25.0%) in 3 of these 11 patients showed an initial response and a subsequent rebound of macular cysts. In 4 eyes (13.8%) of 3 patients, there was no response to treatment but the macular cysts did not worsen when compared to a baseline level. In five additional eyes (17.3%) of 4 patients, there was also no response to treatment and the macular cysts worsened when compared to a baseline level. Sixteen eyes (55.2%) of 12 patients had improvement in VA by ≥7 letters in at least one eye at the most recent FU visit. Seventeen eyes (58.6%) of 10 patients showed a reduction in the CFZ thickness in at least one eye when compared to the pretreatment level. Conclusion: In our cohort of XLRS patients, we observed that such patients have the potential to experience a beneficial effect from sustained treatment of 2% dorzolamide.
Issue Date: 2010-02
Publisher: American Medical Association
Citation Info: Genead MA, Fishman GA, Walia S. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol. 2010 Feb;128(2):190-7. DOI: 10.1001/archophthalmol.2009.398
Type: Article
Description: Postprint version of article may differ from published version. The definitive version is available at DOI: 10.1001/archophthalmol.2009.398
ISSN: 1538-3601
Date Available in INDIGO: 2011-01-24

This item appears in the following Collection(s)

Show full item record


Country Code Views
United States of America 724
China 152
Russian Federation 31
Ukraine 17
Germany 16


My Account


Access Key